Recent investigations into the dynamics of EVs protein biomarkers in NSCLC have revealed that an increase in EVs PD-L1 levels after ICIs treatment is associated with adverse reactions and poor survival outcomes (137). Here, CD274 is linked to non-small cell lung carcinoma.